Other

This study details the analytical validation of the Illumina TruSight Oncology 500 (TSO500) assay within a CAP-certified clinical laboratory in Brazil. It also presents real-world findings from Comprehensive Genomic Profiling (CGP) performed on 454 patients with solid tumors. The research highlighted the genomic landscape of these tumors, including the detection of both novel and canonical gene fusions. The analytical performance of the assay was assessed, demonstrating high specificity and positive predictive value. The authors conclude that TSO500 provides crucial insights for diagnosis, prognosis, and treatment decisions in oncology.

This article introduces OLIVE, a rule-constrained large language model (LLM) framework designed for somatic variant interpretation in clinical oncology. The system integrates gene-specific biology, tumor context, and multiple evidence sources to classify variants. Evaluated on 200 clinical next-generation sequencing cases, OLIVE demonstrated a mean concordance of 97.5% with historical laboratory classifications. Observed discordances were primarily attributed to interpretive ambiguity or evolving evidence rather than model instability, and were deemed equally valid by expert adjudication. These findings indicate that OLIVE can reproducibly support expert somatic variant interpretation in a real-world clinical setting.

This study conducted a detailed micro-costing analysis of implementing whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) in routine clinical care for cancer patients. The primary goal was to identify the key cost drivers hindering the widespread adoption of these comprehensive diagnostic technologies. Researchers developed a multidimensional costing model, which revealed that consumables, particularly flow cells, represent the main expenditure. While personnel and equipment costs decreased with increasing sample volumes, consumable and data processing/storage costs remained largely unchanged. The conclusion emphasizes that falling consumable prices are crucial for broader integration of WGS/WTS as a clinical-grade test.

The SMC5/6 complex is crucial for genome stability, with germline variants linked to genomic instability. This pan-cancer analysis demonstrates that deleterious somatic variants in SMC5/6 genes, but not copy number alterations, are associated with an elevated tumor mutational burden (TMB). This mutagenesis is largely attributed to polymerase epsilon dysfunction and mismatch repair deficiency. Patients with these SMC5/6 variants exhibit improved survival, partly due to a superior response to immunotherapy. These findings indicate that SMC5/6 gene status could serve as a prognostic and predictive biomarker for tailored therapeutic strategies.